The AAPS Journal

, Volume 7, Issue 4, pp E914–E921 | Cite as

Role of animal models in the study of drug-induced hypersensitivity reactions

Article

Abstract

Drug-induced hypersensitivity reactions (DHRs) are a major problem, in large part because of their unpredictable nature. If we understood the mechanisms of these reactions better, they might be predictable. Their unpredictable nature also makes mechanistic studies very difficult, especially prospective clinical studies. Animal models are vital to most biomedical research, and they are almost the only way to test basis hypotheses of DHRs, such as the involvement of reactive metabolites. However, useful animal models of DHRs are rare because DHRs are also unpredictable in animals. For example, sulfonamide-induced DHRs in large-breed dogs appear to be valid because they are very similar to the DHRs that occur in humans; however, the incidence is only ∼0.25%, and large-breed dogs are difficult to use as an animal model. Two more practical models are penicillamine-induced auto-immunity in the Brown Norway rat and nevirapine-induced skin rash in rats. The toxicity in these models is clearly immune mediated. In other models, such as amodiaquine-induced agranulocytosis/hepatotoxicity and halothane-induced hepatotoxicity, the drug induces an immune response but there is no clinical toxicity. This finding suggests that regulatory mechanisms usually limit toxicity. Many of the basic characteristics of the penicillamine and nevirapine models, such as memory and tolerance, are quite different suggesting that the mechanisms are also significantly different. More animal models are needed to study the range of mechanisms involved in DHRs; without them, progress in understanding such reactions is likely to be slow.

Keywords

animal models hypersensitivity reactions idiosyncratic drug reactions penicillamine nevirapine popliteal lymph node assay 

References

  1. 1.
    Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system.Chem Res Toxicol. 1999;12:387–395PubMedCrossRefGoogle Scholar
  2. 2.
    Knowles SR, Uetrecht JP, Shear NH. Confirming false adverse reactions to drugs by performing individualized, randomized trials.Can J Clin Pharmacol. 2002;9:149–153.PubMedGoogle Scholar
  3. 3.
    Macy E. Multiple antibiotic allegry syndrome.Immunol Allergy Clin North Am. 2004;24:533–543.PubMedCrossRefGoogle Scholar
  4. 4.
    Jaffe IA. Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.Springer Semin Immunopathol. 1981;4:193–207.PubMedCrossRefGoogle Scholar
  5. 5.
    Weiss AS, Markenson JA, Weiss MS, Kammerer WH. Toxicity of D-penicillamine in rheumatoid arthritis: a report of 63 patients including 2 with aplastic anemia and one with the nephrotic syndrome.Am J Med. 1978;64:114–120.PubMedCrossRefGoogle Scholar
  6. 6.
    Stein HB, Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS. Adverse effects of D-penicillamine in rheumatoid arthritis.Ann Intern Med. 1980;92:24–29.PubMedGoogle Scholar
  7. 7.
    Donker AJ, Venuto RC, Vladutiu AO, Brentjens JR, Andres GA. Effects of prolonged administration of D-penicillamine or captopril in various strains of rats.Clin Immunol Immunopathol. 1984;30:142–155.PubMedCrossRefGoogle Scholar
  8. 8.
    Tournade H, Pelletier L, Pasquier R, Vial M, Mandet C, Druet P. D-Penicillamine-induced autoimmunity in Brown-Norway rats: similarities with HgCl2-induced autoimmunity.J Immunol. 1990;144:2985–2991.PubMedGoogle Scholar
  9. 9.
    Masson MJ, Uetrecht JP. Tolerance induced by low dose D-penicillamine in the Brown Norway rat model of drug-induced autoimmunity is immune-mediated.Chem Res Toxicol. 2004;17:82–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Seguin B, Masson MJ, Uetrecht J. D-penicillamine-induced autoimmunity in the Brown Norway rat: role for both T and non-T splenocytes in adoptive transfer of tolerance.Chem Res Toxicol. 2004;17:1299–1302.PubMedCrossRefGoogle Scholar
  11. 11.
    Sayeh E, Uetrecht JP. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm.Toxicology, 2001;163:195–211.PubMedCrossRefGoogle Scholar
  12. 12.
    Seguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. Gene expression profiling in a model of d-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger.Chem Res Toxicol. 2005;18:1193–1202.PubMedCrossRefGoogle Scholar
  13. 13.
    Masson MJ, Teranishi M, Shenton JM, Uetrecht JP. Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat.J Immunotoxicol. 2004;1:79–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Rhodes J. Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation.J Immunol. 1989;143:1482–1489.PubMedGoogle Scholar
  15. 15.
    Uetrecht J. Current trends in drug-induced autoimmunity.Autoimmun Rev. 2005:4:309–314.PubMedCrossRefGoogle Scholar
  16. 16.
    Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash.Clin Infect Dis. 2001;32:124–129.PubMedCrossRefGoogle Scholar
  17. 17.
    Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, Uetrecht JP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.Chem Res Toxicol. 2003;16:1078–1089.PubMedCrossRefGoogle Scholar
  18. 18.
    Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown norway ratChem Res Toxicol. 2005;18:1799–1813.PubMedCrossRefGoogle Scholar
  19. 19.
    Aucoin DP, Peterson ME, Hurvitz AI, et al. Propylthiouracil-induced immune-mediated disease in the cat.J Pharmacol Exp Ther. 1985;234:13–18.PubMedGoogle Scholar
  20. 20.
    Aucoin DP, Rubin RL, Peterson ME, et al. Dose-dependent induction of antinative DNA antibodies in cats by propylthiouracil.Arthritis Rheum. 1988;31:688–692.PubMedCrossRefGoogle Scholar
  21. 21.
    Waldhauser L, Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat.Toxicology. 1996;114:155–162.PubMedCrossRefGoogle Scholar
  22. 22.
    Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis.Drug Metab Dispos. 1991;19:354–359.PubMedGoogle Scholar
  23. 23.
    Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview.Semin Arthritis Rheum. 1999;28:392–397.PubMedCrossRefGoogle Scholar
  24. 24.
    Nässberger L, Sjöholm AG, Jonsson H, Sturfelt G, Åkesson A. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.Clin Exp Immunol. 1990;81:380–383.PubMedCrossRefGoogle Scholar
  25. 25.
    Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog.J Vet Pharmacol Ther. 2004;27:129–138.PubMedCrossRefGoogle Scholar
  26. 26.
    Zimmerman H.Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver; Philadelphia, PA: Lippincott Williams & Wilkins. 1999.Google Scholar
  27. 27.
    Kenna JG, Neuberger J, Williams R. Identification by immunoblotting of 3 halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis.J Pharmacol Exp Ther. 1987;242:733–740.PubMedGoogle Scholar
  28. 28.
    Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.Proc Natl Acad Sci USA. 1989;86:322–326.PubMedCrossRefGoogle Scholar
  29. 29.
    Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis.Chem Res Toxicol. 1996;9:1159–1166.PubMedCrossRefGoogle Scholar
  30. 30.
    McLain GE, Sipes IG, Brown BR. An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia.Anesthesiology 1979;51:321–326.PubMedCrossRefGoogle Scholar
  31. 31.
    Furst SM, Luedke D, Gaw HH, Reich R, Gandolfi AJ. Demonstration of a cellular immune response in halothane-exposed guinea pigs.Toxicol Appl Pharmacol. 1997;143:245–255.PubMedCrossRefGoogle Scholar
  32. 32.
    Maggs JL, Tingle MD, Kitteringham NR, Park BK. Drug-protein conjugates-XIV: mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin, and hepatoxin in man.Biochem Pharmacol. 1988;37:303–311.PubMedCrossRefGoogle Scholar
  33. 33.
    Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.IntArch Allergy Appl Immunol. 1991;95:369–375.Google Scholar
  34. 34.
    Clarke JB, Maggs JL, Kitteringham NR, Park BK. Immunogenicity of amodiaquine in the rat.Int Arch Allergy Appl Immunol. 1990;91:335–342.PubMedGoogle Scholar
  35. 35.
    Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo.J Pharmacol Exp Ther. 1980;213:364–369.PubMedGoogle Scholar
  36. 36.
    Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA, Wright JM. A model of isoniazid-induced hepatotoxicity in rabbits.J Pharmacol Toxicol Methods. 1995;34:109–116.PubMedCrossRefGoogle Scholar
  37. 37.
    Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idioxyncrasy-like liver injury in rats.J Pharmacol Exp Ther. 2003;307:9–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, Roth RA. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine.J Pharmacol Exp Ther. 2005:314:1023–1031.PubMedCrossRefGoogle Scholar
  39. 39.
    Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy: is there a connection?,J Pharmacol Exp Ther. 2003;307:1–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Pieters R, Ezendam J, Bleumink R, Bol M, Nierkens S. Predictive testing for autoimmunity.Toxicol Lett. 2002;127:83–91.PubMedCrossRefGoogle Scholar
  41. 41.
    Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.Chem Res Toxicol. 2004;17:3–16.PubMedCrossRefGoogle Scholar
  42. 42.
    Bloksma N, Kubicka-Muranyi M, Schuppe H, Gleichmann E, Gleichmann H. Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats.Crit Rev Toxicol. 1995;25:369–396.PubMedCrossRefGoogle Scholar
  43. 43.
    Gutting BW, Schomaker SJ, Kaplan AH, Amache DE. A comparison of the direct and reporter antigen popliteal lymph node assay for the detection of immunomodulation by low molecular weight compounds.Toxicol Sci. 1999;51:71–79.PubMedCrossRefGoogle Scholar
  44. 44.
    Nierkens S, Nieuwenhuijsen L, Thomas M, Pieters R. Evaluation of the use of reporter antigens in an auricular lymph node assay to assess the immunosensitizing potential of drugs.Toxicol Sci. 2004:79:90–97.PubMedCrossRefGoogle Scholar
  45. 45.
    Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK, Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes.J Pharmacol Exp Ther. 2005;314:43–52.PubMedCrossRefGoogle Scholar
  46. 46.
    Kammueller ME, Seinen W. Structural requirements for hydantoins and 2-thiohydantoins to induce lymphoproliferative popliteal lymph node reactions in the mouse.Int J Immunopharmacol. 1988;10:997–1010.CrossRefGoogle Scholar
  47. 47.
    Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.Nat Rev Immunol. 2004;4:469–478.PubMedCrossRefGoogle Scholar
  48. 48.
    Wooley PH, Whalen JD. Pristane-induced arthritis in mice. III. Lymphocyte phenotypic and functional abnormalities precede the development of pristane-induced arthritis.Cell Immunol. 1991;138:251–259.PubMedCrossRefGoogle Scholar
  49. 49.
    Albers R, Broeders A, van der Pijl A, Seinen W, Pieters R. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals.Toxicol Appl Pharmacol. 1997;143:102–109.PubMedCrossRefGoogle Scholar
  50. 50.
    Nierkens S, Aalbers M, Bol M, van Wijk F, Hassing I, Pieters R. Development of an oral exposure mouse model to predict drug-induced hypersensitivity reactions by using reporter antigens.Toxicol Sci. 2005;83:273–281.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2005

Authors and Affiliations

  1. 1.Department of Pharmacology, Clinical Pharmacology and ToxicologyUniversity of TorontoTorontoCanada

Personalised recommendations